Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations

Yeon J. Lee,Khaja Syed,Oriol Busquets,Hanqin Li,Jesse Dunnack,Atehsa Sahagun,Helen S. Bateup,Frank Soldner,Dirk Hockemeyer,Donald C. Rio

DOI: https://doi.org/10.1101/2024.02.28.582420

2024-03-12

Abstract:Parkinson’s disease (PD) is a devastating neurodegenerative disorder, with both genetic and environmental causes. Human genetic studies have identified ∼20 inherited familial genes that cause monogenic forms of PD. We have investigated the effects of individual familial PD mutations by developing a medium-throughput platform using genome-editing to install individual PD mutations in human pluripotent stem cells (hPSCs) that we subsequently differentiated into midbrain lineage cells including dopaminergic (DA) neurons in cell culture. Both global gene expression and pre-mRNA splicing patterns in midbrain cultures carrying inherited, pathogenic PD mutations in the PRKN and SNCA genes were analyzed. This analysis revealed that PD mutations lead to many more pre-mRNA splicing changes than changes in overall gene RNA expression levels. Importantly, we have also shown that these splicing changes overlap with changes found in PD patient postmortem brain sample RNA-seq datasets. These pre-mRNA splicing changes are in genes related to cytoskeletal and neuronal process formation, as well as splicing factors and spliceosome components. We predict that these mutation-specific pre-mRNA isoforms can be used as biomarkers for PD that are linked to the familial PD mutant genotypes.

Neuroscience

What problem does this paper attempt to address?

The main aim of this paper is to investigate how gene mutations related to Parkinson's disease (PD) affect precursor mRNA splicing patterns and gene expression, and to explore whether these changes can serve as biomarkers for PD.

Specifically, the research team established a medium-throughput platform using human pluripotent stem cells (hPSCs). This platform utilized gene editing technology to introduce gene mutations associated with familial Parkinson's disease, such as the exon 3 deletion (Ex3del) of the PRKN gene and the A30P mutation of the SNCA gene. These cells were then differentiated into midbrain lineage cells, including dopaminergic neurons, to simulate the PD pathological process in vitro.

Key findings of the study include:
1. **Changes in precursor mRNA splicing patterns**: Compared to changes in overall gene expression levels, PD-related gene mutations led to numerous changes in precursor mRNA splicing patterns. These changes mainly occurred in genes related to cytoskeleton organization, regulation of neurogenesis, and other functions.
2. **Comparison with PD patient samples**: The study also compared the splicing pattern changes in these cell models with RNA sequencing data from post-mortem brain tissue samples of PD patients. The results showed significant overlapping splicing changes, suggesting that the observed changes might be related to PD pathophysiology.
3. **Changes in specific splicing factors**: The study particularly focused on several splicing factors, such as RBFOX1, DDX46, and SRRM2, whose precursor mRNA splicing patterns were altered in both PD patient brain samples and hPSC-derived dopaminergic neurons. These changes could further affect the splicing of multiple other precursor mRNAs, thereby impacting protein function.

In summary, this study reveals how PD-related gene mutations affect precursor mRNA splicing patterns and suggests that these specific splicing changes could serve as potential biomarkers for the diagnosis and treatment of PD.